Controlled delivery of STING agonist and manganese ion in injectable PLGA implants for enhanced cancer immunotherapy.

ABSTRACT: The cGAS-STING pathway plays a central role in innate immune sensing of cancer and represents a promising target for cancer immunotherapy. We previously demonstrated that nutritional metal ions, such as manganese (Mn²⁺), can potentiate cGAS-STING signaling, amplifying IFN-I responses and driving innate and adaptive anti-tumor immunity. Here, we expand on this concept by developing a controlled-release CDA-Mn²⁺ PLGA milli-cylinder implant, designed for a single dose treatment for cancer immunotherapy. Using solvent-extrusion, we formulated poly(D,l-lactide-co-glycolide) (PLGA) 50/50 milli-cylinder implants (I.D. = 0.8 mm) loaded with cyclic di-adenosine monophosphate (CDA) and Mn²⁺, achieving high encapsulation efficiency and tunable, sustained release kinet

SUBMITTER: Kodamasimham S 

PROVIDER: S-EPMC12831163 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature